Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Seagen Inc.
Kivu Bioscience Inc.
AstraZeneca
STORM Therapeutics LTD
Eli Lilly and Company
Neonc Technologies, Inc.
EMD Serono
Arcus Biosciences, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Seagen Inc.
Pfizer
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
Genentech, Inc.
Clasp Therapeutics, Inc.
Exscientia AI Limited
Normunity AccelCo, Inc.
Eli Lilly and Company
Poseida Therapeutics, Inc.
DualityBio Inc.
MacroGenics
SystImmune Inc.
Eli Lilly and Company
Radiopharm Theranostics, Ltd
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Novartis
Elephas
OncoNano Medicine, Inc.
GlaxoSmithKline
Fate Therapeutics
Seagen Inc.
Tanabe Pharma America, Inc.
NeoTX Therapeutics Ltd.
Therorna
HiFiBiO Therapeutics
DualityBio Inc.
BicycleTx Limited
Volastra Therapeutics, Inc.
AstraZeneca
LigaChem Biosciences, Inc.
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Guardant Health, Inc.
Bicara Therapeutics